Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

Phase 1 data suggest that WVE-007, an investigational siRNA drug given by injection, leads to reductions in visceral fat, waist circumference, and body weight.

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p<0.05) and total fat (-5%), stabilization ...

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company ...

IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and ...

IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN ...

The analysis shows that lower tax rates under the composition scheme significantly improve liquidity for startups. This enables reinvestment into growth without relying on external ...

The seats with the lowest deletions from the pre-adjudication to the post-adjudication roll are Manbazar, Onda, Kashipur, Jhargram , and Chhatna.

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p0.05) and total fat (-5%), stabilization ...

Despite the Phase I data being less impressive than expected, Wave will still initiate the Phase IIa portion of the study.

Researchers have developed a volcanic rock formula that cuts carbon emissions by 67%, potentially offering an affordable ...

Structure Therapeutics' Phase 2 data for Aleniglipron show 16% weight loss at 44 weeks with strong tolerability and no safety ...